13 April 2017 in Annals of Oncology
Pembrolizumab and nivolumab are immune checkpoint inhibitors targeting PD-1 that have recently been approved in pretreated recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. In the clinic, some patients seem not only not to benefit from anti-PD-L1/PD-1 agents but rather to experience an acceleration of tumor growth kinetics (TGK). We retrospectively compared TGK on immunotherapy and TGK on last treatment in patients with R/M HNSCC treated with PD-1/PD-L1 inhibitors in four French centers. The TGK ratio (TGKR, ratio of the slope of tumor growth before treatment and the slope of tumor growth on treatment) was calculated. Hyperprogression was defined as a TGKR ≥ 2. From September 2012 to September 2015, 34 patients were identified. Patterns of recurrence included exclusive loco-regional recurrence in 14 patients, exclusive distant metastases in 11 patients, and both in 9 patients. No pseudo-progression was observed. Hyperprogression was observed in 10 patients (29%), including 9 patients with at least a locoregional recurrence, and only 1 patient with exclusively distant metastases. Hyperprogression significantly correlated with a regional recurrence (TGKR ≥ 2: 90% versus TGKR < 2: 37%, P = 0.008), but not with local or distant recurrence. Hyperprogression was associated with a shorter progression-free survival (PFS) according to RECIST (P = 0.003) and irRECIST (P = 0.02), but not with overall survival (P = 0.77). Hyperprogression was observed in 29% of patients with R/M HNSCC treated with anti-PD-L1/PD-1 agents and correlated with a shorter PFS. It occurred in 39% of patients with at least a locoregional recurrence and 9% of patients with exclusively distant metastases. No pseudo-progressions were reported. Mechanisms and causality of hyperprogression should further be assessed through prospective controlled studies.
1 December 2017 in European Journal of Cancer
1 January 2018 in ESMO Open
Background Cetuximab is crucial in the management of squamous cell carcinoma of the head and neck of patients. Grade 3–4 cetuximab-induced infusion reactions (CI-IRs) occur in 2% of patients with colorectal cancer. Despite the 2.7% CI-IR rate in the EXTREME trial, higher rates were reported in small series of patients with head and neck squamous cell carcinoma (HNSCC) (6%–18%). There is an urgent need to better appraise the natural history and the predictive factors for CI-IRs in patients with HNSCC exposed to cetuximab. Methods The medical records from patients with HNSCC (n=428) treated by cetuximab at Gustave Roussy from January 2013 to December 2015 were reviewed. The impact of potential risk factors was analysed. Results Out of 428 patients, 24 patients (5.4%) presented CI-IR, including grade 3–4 (95.7%); about 21% (5/24) requiring intensive care unit referral and quasi all occurred within the first cycle (21/24). In a multivariate analysis, the occurrence of grade 3–4 CI-IR was associated with tobacco and alcohol history (p=8.5e–3) and with prior allergy history (p=2.9e–3). CI-IRs tended to be associated with poor overall survival in patients with recurrent and metastatic HNSCC and with a higher number of further lines of chemotherapy. Conclusion In real life, CI-IRs appear far more common in patients with HNSCC (5.4%) than reported in prospective trials. This is the largest series of patients ever focusing on the risk of CI-IR in patients with HNSCC. Prior allergy history and tobacco history are associated with CI-IR and could be used to better allocate treatment. Further prospective data are required to confirm these findings.
20 May 2016 in Journal of Clinical Oncology
6072 Background: About 20% of R/M HNSCC pts have an objective response with anti-PD1/PD-L1 inhibitors after platinum failure. Some pts, however, experience a rapid flare-up during treatment. We evaluated the relationship between a flare-up occurence and the patterns of recurrence in R/M HNSCC pts treated with anti-PD1/PD-L1. Methods: Data from R/M HNSCC pts treated with anti-PD1/PD-L1 in 4 French Cancer Centers between 09/2012 and 09/2015 were retrospectively collected. Pts had an imaging performed at least 2 weeks prior to baseline imaging to estimate tumor growth kinetics (TGK) before and on immunotherapy. TGK before starting immunotherapy (TGKPRE ) was defined as the difference of the sum of the largest diameters of the target lesions (according to RECIST) per unit of time between pre-baseline and baseline imaging, while TGK on immunotherapy (TGKPOST ) was defined as the same difference between baseline and last imaging performed on treatment. The TGK ratio (TGKR ) was defined as TGKPOST / TGKPRE . A flare-up was defined as a TGKR > 1, while 0 < TGKR ≤ 1 and TGKR < 1 indicated tumor deceleration and tumor shrinkage, respectively. An exact Fisher test was used for statistical comparison. Results: Thirty-five pts with available pre-baseline imaging and evaluable disease were identified. Median age was 63 years [35-84], 28 pts were male (80%). Primary tumor location was oral cavity, oropharynx, larynx, and hypopharynx in 12 (34%), 12 (34%), 5 (14%), and 6 (17%) pts, respectively. Patterns of recurrence included exclusive distant metastases in 11 pts (31%), exclusive loco-regional recurrence in 14 pts (40%), and both in 10 pts (29%). Ten pts (29%) experienced a flare-up, while 8 pts (23%) had tumor shrinkage and 17 pts (49%) a deceleration of tumor growth. Interestingly, a flare-up was observed in none of the 11 pts (0%) with exclusive distant metastases, in 5/14 pts (36%) with exclusive loco-regional recurrence, and in 5/10 pts (50%) with loco-regional recurrence and distant metastases (p = 0.06). Conclusions: Our preliminary results suggest that anti-PD1/PDL1 should be used cautiously in R/M HNSCC pts with loco-regional recurrence.
13 April 2015 in PLOS ONE
CGCristina Gómez-Fernández
JAJose Antonio Avilés-Izquierdo
Jose Antonio Avilés-Izquierdo
S(Spanish Multidisciplinary Group of Melanoma (GEM)
Spanish Multidisciplinary Group of Melanoma (GEM)
+20
Familial history of melanoma is a well-known risk factor for the disease, and 7% melanoma patients were reported to have a family history of melanoma. Data relating to the frequency and clinical and pathological characteristics of both familial and non-familial melanoma in Spain have been published, but these only include patients from specific areas of Spain and do not represent the data for the whole of Spain. An observational study conducted by the Spanish Group of Melanoma (GEM) analyzed the family history of patients diagnosed with melanoma between 2011 and 2013 in the dermatology and oncology departments. In all, 1047 patients were analyzed, and 69 (6.6%) fulfilled criteria for classical familial melanoma (two or more first-degree relatives diagnosed with melanoma). Taking into account other risk factors for familial melanoma, such as multiple melanoma, pancreatic cancer in the family or second-degree relatives with melanoma, the number of patients fulfilling the criteria increased to 165 (15.8%). Using a univariate analysis, we determined that a Breslow index of less than 1 mm, negative mitosis, multiple melanoma, and a history of sunburns in childhood were more frequent in familial melanoma patients, but a multivariate analysis revealed no differences in any pathological or clinical factor between the two groups. Similar to that observed in other countries, familial melanoma accounts for 6.6% of melanoma diagnoses in Spain. Although no differences in the multivariate analysis were found, some better prognosis factors, such as Breslow index, seem more frequent in familial melanoma, which reflect a better early detection marker and/or a different biological behavior.